Accéder au contenu
Merck
Toutes les photos(1)

Documents

V8261

Sigma-Aldrich

(±)-Vigabatrin

Synonyme(s) :

(R,S)-4-Amino-5-hexenoic acid, (±)-γ-Vinyl-GABA, (±)-4-Aminohexenoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H11NO2
Numéro CAS:
68506-86-5
Poids moléculaire :
129.16
Numéro CE :
270-929-6
Numéro MDL:
MFCD00274577
Code UNSPSC :
12352200
ID de substance PubChem :
24278202
Nomenclature NACRES :
NA.77

Niveau de qualité

200

Auteur

Lundbeck

Chaîne SMILES 

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

Clé InChI

PJDFLNIOAUIZSL-UHFFFAOYSA-N

Informations sur le gène

human ... ABAT(18) , GABBR1(2550) , GABBR2(9568) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

Irreversible GABA transaminase inhibitor. Increases intracellular concentration of GABA in nerve endings; possesses antiepileptic activity.

Caractéristiques et avantages

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABA Transporters, GABAA Receptors and Glutamate/GABA Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Lundbeck. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H372

Classification des risques

STOT RE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

R S Fisher
Brain research. Brain research reviews, 14(3), 245-278 (1989-07-01)
The study of mechanisms of the epilepsies requires employment of animal models. Choice of a model system depends upon several factors, including the question to be studied, the type of epilepsy to be modelled, familiarity and convenience. Over 50 models
The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
Dorota Nieoczym et al.
Progress in neuro-psychopharmacology & biological psychiatry, 39(1), 129-135 (2012-06-12)
Sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor, has recently been reported to affect convulsant activity in some animal models of seizures and epilepsy. Moreover, its influence on the protective activity of some antiepileptic drugs (AEDs) was also noted. The aim
M Iu Dorofeeva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(6 Pt 2), 27-31 (2012-09-18)
Tuberous sclerosis complex is a multisystem genetic disorder. Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time. Onset usually occurs during childhood and up to one third of children with tuberous sclerosis
Mi-Sun Yum et al.
Journal of child neurology, 28(3), 308-313 (2012-07-04)
Tuberous sclerosis complex is a genetic disorder resulting in epilepsy and mental retardation. Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have
Afficher tous les articles scientifiques apparentés

Contenu apparenté

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique